Israeli scientists and international colleagues offer proof of concept to ameliorate the effects of rare congenital neurological disorder (Allan-Herndon-Dudley Syndrome)
Preclinical studies identify possible new therapies for patients with Allan-Herndon-Dudley Syndrome
Two recent discoveries by Israeli scientist and his international colleagues may lead to new ways to treat patients with Allan-Herndon-Dudley syndrome (AHDS), a rare brain development disorder that causes severe intellectual disability and problems with movement.
In the study, published in the peer-reviewed journal Thyroid, scientists identified a gene therapy approach that can potentially help prevent or reduce the devastating neurological symptoms in patients diagnosed with AHDS.
“The ability of this gene therapy approach to provide long-term rescue of neurological phenotypes in this mouse model is an important proof of concept to move this therapy to humans,” said Dr. Gad Vatine, , the lead author of the study. “This study helps pave the way for promising treatments that could alleviate the neurological symptoms in AHDS patients.”
“There currently are no successful therapies for treating the neurological symptoms that occur as a result of this condition,” said co-corresponding author Prof. Clive Svendsen.
“However, we’re finding gene therapies to be a promising new way to treat developmental neurological disorders, like AHDS.”
The disorder, typically diagnosed in childhood and only in males, is caused by a mutation in a thyroid hormone “transporter” known as MCT8, that is tasked with carrying thyroid hormones across the blood-brain barrier and into brain cells.
This process is critical for human brain development and function.
A breakdown in the process leads to serious intellectual disability and problems with speech and movement. Most affected children do not walk or talk.
To counteract this issue, investigators tested the potential of a viral gene therapy, AAV9-MCT8, to determine whether it could correct brain defects in mice that carry the mutation and possess symptoms of the disease.
The AAV9 vector acts as a carrier that helps deliver genetic material, like MCT8, into cells.
“We thought we might be able to get the transporter back with an AAV9 vector by genetically modifying it so it will produce the protein MCT8,” said Svendsen.
Once the vector was encoded with MCT8, the team infused it into the bloodstream of juvenile male mice.
“While earlier work showed expression of the MCT8 protein in brains of newborn mice, it was uncertain whether this would also happen when given to young male mice, at a time similar to when most children are diagnosed with the disease,” said co-corresponding author Samuel Refetoff, MD, the Frederick H. Rawson Professor of Medicine, a professor of Pediatrics, Committee on Genetics and director of the Endocrinology Laboratory at the University of Chicago.
In fact, the mice showed an improvement in their learning curve, suggesting that the treatment has beneficial effects on cognitive and motor functions.
The second study, also published in Thyroid, was a collaborative project led by scientists at the Institut fur Biochemie und Molekularbiologie in Germany.
The investigators previously found that the drug sodium phenylbutyrate could help restore MCT8 function in mice with MCT8 deficiency, but they wanted to expand on the work and determine whether the drug could potentially work in humans.
Cedars-Sinai scientists already created a human cell model of AHDS using induced pluripotent stem cells (iPSC), a special kind of stem cell that can produce any type of cell in the body using an individual’s blood sample. Using cells from patients with AHDS, the team was able to model patients’ neurons and the blood-brain barrier in a laboratory dish.
The team in Germany then used this model to test if the drug could also correct MCT8 in human-derived cells. The investigators found that the drug was able to activate MCT8 and restore the thyroid hormone transport function by stabilizing the MCT8 expression and activating additional thyroid hormone transporters.
“We now have two exciting breakthroughs for treating MCT8 deficiencies that might really have an impact on the disease,” Svendsen said.
Both options call for future clinical studies to investigate these treatments in patients with AHDS.